1932

Abstract

Marijuana is becoming legal in an increasing number of states for both medical and recreational use. Considerable controversy exists regarding the public health impact of these changes. The evidence for the legitimate medical use of marijuana or cannabinoids is limited to a few indications, notably HIV/AIDS cachexia, nausea/vomiting related to chemotherapy, neuropathic pain, and spasticity in multiple sclerosis. Although cannabinoids show therapeutic promise in other areas, robust clinical evidence is still lacking. The relationship between legalization and prevalence is still unknown. Although states where marijuana use is legal have higher rates of use than nonlegal states, these higher rates were generally found even prior to legalization. As states continue to proceed with legalization for both medical and recreational use, certain public health issues have become increasingly relevant, including the effects of acute marijuana intoxication on driving abilities, unintentional ingestion of marijuana products by children, the relationship between marijuana and opioid use, and whether there will be an increase in health problems related to marijuana use, such as dependence/addiction, psychosis, and pulmonary disorders. In light of this rapidly shifting legal landscape, more research is urgently needed to better understand the impact of legalization on public health.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-050214-013454
2016-01-14
2024-04-15
Loading full text...

Full text loading...

/deliver/fulltext/med/67/1/annurev-med-050214-013454.html?itemId=/content/journals/10.1146/annurev-med-050214-013454&mimeType=html&fmt=ahah

Literature Cited

  1. 1. Substance Abuse and Mental Health Services Administration 2014. Results from 2013 national survey on drug use and health Rockville, MD: Substance Abuse and Mental Health Serv. Admin.
  2. 2. Marijuana Policy Project 2015. Marijuana prohibition facts https://www.mpp.org/issues/legalization/marijuana-prohibition-facts/
  3. 3. National Organization for the Reform of Marijuana Laws (NORML) 2015. About marijuana http://www.norml.org/marijuana
  4. Potter DJ, Clark P, Brown MB. 4.  2008. Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J. Forensic Sci. 53:190–94 [Google Scholar]
  5. ElSohly MA, Ross SA, Mehmedic Z. 5.  et al. 2000. Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980–1997. J. Forensic Sci. 45:124–30 [Google Scholar]
  6. Mehmedic Z, Chandra S, Slade D. 6.  et al. 2010. Potency trends of Δ9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J. Forensic Sci. 55:51209–17 [Google Scholar]
  7. Ohlsson A, Lindgren JE, Wahlen A. 7.  et al. 1980. Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin. Pharmacol. Ther. 28:3409–16 [Google Scholar]
  8. Beal JE, Olson R, Laubenstein L. 8.  et al. 1995. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J. Pain Symptom Manage. 10:289–97 [Google Scholar]
  9. Beal JE, Olson R, Lefkowitz L. 9.  et al. 1997. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome–associated anorexia. J. Pain Symptom Manage. 14:17–14 [Google Scholar]
  10. Sallan SE, Zinberg NE, Frei E 3rd. 10.  1975. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N. Engl. J. Med. 293:16795–97 [Google Scholar]
  11. Sallan SE, Cronin C, Zelen M, Zinberg NE. 11.  1980. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N. Engl. J. Med. 302:3135–38 [Google Scholar]
  12. Orr LE, McKernan JF, Bloome B. 12.  1980. Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Arch. Intern. Med. 140:111431–33 [Google Scholar]
  13. Herman TS, Einhorn LH, Jones SE. 13.  et al. 1979. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N. Engl. J. Med. 300:231295–97 [Google Scholar]
  14. Zajicek J, Fox P, Sanders H. 14.  et al. 2003. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362:93951517–26 [Google Scholar]
  15. Wade DT, Makela P, Robson P. 15.  et al. 2004. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Multiple Sclerosis 10:4434–41 [Google Scholar]
  16. Corey-Bloom J, Wolfson T, Gamst A. 16.  et al. 2012. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. Can. Med. Assoc. J. 184:101143–50 [Google Scholar]
  17. Zajicek JP, Hobart JC, Slade A. 17.  et al. 2012. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J. Neurol. Neurosurg. Psychiatry 83:111125–32 [Google Scholar]
  18. Abrams DI, Jay CA, Shade SB. 18.  et al. 2007. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 68:7515–21 [Google Scholar]
  19. Ellis RJ, Toperoff W, Vaida F. 19.  et al. 2009. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 34:3672–80 [Google Scholar]
  20. Ware MA, Wang T, Shapiro S. 20.  et al. 2010. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. Can. Med. Assoc. J. 182:14E694–701 [Google Scholar]
  21. Serpell M, Ratcliffe S, Hovorka J. 21.  et al. 2014. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. Eur. J. Pain 18:7999–1012 [Google Scholar]
  22. Nurmikko TJ, Serpell MG, Hoggart B. 22.  et al. 2007. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 133:1210–20 [Google Scholar]
  23. Nagarkatti P, Pandey R, Rieder SA. 23.  et al. 2009. Cannabinoids as novel anti-inflammatory drugs. Future Med. Chem. 1:71333–49 [Google Scholar]
  24. Hill TD, Cascio MG, Romano B. 24.  et al. 2013. Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. Br. J. Pharmacol. 170:3679–92 [Google Scholar]
  25. Volicer L, Stelly M, Morris J. 25.  et al. 1997. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int. J. Geriatr. Psychiatry 12:9913–19 [Google Scholar]
  26. Strasser F, Luftner D, Possinger K. 26.  et al. 2006. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J. Clin. Oncol. 24:213394–400 [Google Scholar]
  27. Jatoi A, Windschitl HE, Loprinzi CL. 27.  et al. 2002. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J. Clin. Oncol. 20:2567–73 [Google Scholar]
  28. Naftali T, Bar-Lev Schleider L, Dotan I. 28.  et al. 2013. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clin. Gastroenterol. Hepatol. 11:101276–80.e1 [Google Scholar]
  29. Cunha JM, Carlini EA, Pereira AE. 29.  et al. 1980. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21:3175–85 [Google Scholar]
  30. Ames FR, Cridland S. 30.  1986. Anticonvulsant effect of cannabidiol. S. Afr. Med. J. 69:114 [Google Scholar]
  31. Mechoulam R, Carlini EA. 31.  1978. Toward drugs derived from cannabis. Naturwissenschaften 65:4174–79 [Google Scholar]
  32. Gloss D, Vickrey B. 32.  2014. Cannabinoids for epilepsy. Cochrane Database Syst. Rev. 3:CD009270 [Google Scholar]
  33. Rog DJ, Nurmikko TJ, Friede T, Young CA. 33.  2005. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 65:6812–19 [Google Scholar]
  34. Berman JS, Symonds C, Birch R. 34.  2004. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 112:3299–306 [Google Scholar]
  35. Blake DR, Robson P, Ho M. 35.  et al. 2006. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 45:150–52 [Google Scholar]
  36. Jetly R, Heber A, Fraser G, Boisvert D. 36.  2015. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology 51:585–88 [Google Scholar]
  37. Novotna A, Mares J, Ratcliffe S. 37.  et al. 2011. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur. J. Neurol. 18:91122–31 [Google Scholar]
  38. Notcutt W, Langford R, Davies P. 38.  et al. 2012. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols). Multiple Sclerosis 18:2219–28 [Google Scholar]
  39. Bitencourt RM, Pamplona FA, Takahashi RN. 39.  2008. Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats. Eur. Neuropsychopharmacol. 18:12849–59 [Google Scholar]
  40. Rabinak CA, Angstadt M, Sripada CS. 40.  et al. 2013. Cannabinoid facilitation of fear extinction memory recall in humans. Neuropharmacology 64:396–402 [Google Scholar]
  41. Tomida I, Azuara-Blanco A, House H. 41.  et al. 2006. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J. Glaucoma 15:5349–53 [Google Scholar]
  42. Choo EK, Benz M, Zaller N. 42.  et al. 2014. The impact of state medical marijuana legislation on adolescent marijuana use. J. Adolescent Health 55:2160–66 [Google Scholar]
  43. Wall MM, Poh E, Cerda M. 43.  et al. 2011. Adolescent marijuana use from 2002 to 2008: higher in states with medical marijuana laws, cause still unclear. Ann. Epidemiol. 21:9714–16 [Google Scholar]
  44. Cerda M, Wall M, Keyes KM. 44.  et al. 2012. Medical marijuana laws in 50 states: investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence. Drug Alcohol Dep. 120:1–322–27 [Google Scholar]
  45. Volkow ND, Baler RD, Compton WM, Weiss SR. 45.  2014. Adverse health effects of marijuana use. N. Engl. J. Med. 370:232219–27 [Google Scholar]
  46. Radhakrishnan R, Wilkinson ST, D'Souza DC. 46.  2014. Gone to pot—a review of the association between cannabis and psychosis. Front. Psychiatry 5:54 [Google Scholar]
  47. Meier MH, Caspi A, Ambler A. 47.  et al. 2012. Persistent cannabis users show neuropsychological decline from childhood to midlife. PNAS 109:40E2657–64 [Google Scholar]
  48. Fergusson DM, Boden JM. 48.  2008. Cannabis use and later life outcomes. Addiction 103:6969–76 [Google Scholar]
  49. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. 49.  2010. Monitoring the future: national survey results on drug use, 1975–2009. Volume I: secondary school students. NIH Publ. No. 10–7584. Natl. Inst. Drug Abuse
  50. Pacek LR, Mauro PM, Martins SS. 50.  2015. Perceived risk of regular cannabis use in the United States from 2002 to 2012: differences by sex, age, and race/ethnicity. Drug Alcohol Dep. 149:232–44 [Google Scholar]
  51. Schuermeyer J, Salomonsen-Sautel S, Price RK. 51.  et al. 2014. Temporal trends in marijuana attitudes, availability and use in Colorado compared to non-medical marijuana states: 2003–11. Drug Alcohol Dep. 140:145–55 [Google Scholar]
  52. Lynne-Landsman SD, Livingston MD, Wagenaar AC. 52.  2013. Effects of state medical marijuana laws on adolescent marijuana use. Am. J. Public Health 103:81500–6 [Google Scholar]
  53. Ammerman S, Ryan S, Adelman WP. 53.  2015. The impact of marijuana policies on youth: clinical, research, and legal update. Pediatrics 135:3e769–85 [Google Scholar]
  54. Ogden DW. 54.  2015. Memorandum for selected United States attorneys: investigations and prosecutions in states authorizing the medical use of marijuana 2009. http://www.justice.gov/opa/documents/medical-marijuana.pdf
  55. Salomonsen-Sautel S, Min SJ, Sakai JT. 55.  et al. 2014. Trends in fatal motor vehicle crashes before and after marijuana commercialization in Colorado. Drug Alcohol Dep. 140:137–44 [Google Scholar]
  56. Sznitman SR, Zolotov Y. 56.  2015. Cannabis for therapeutic purposes and public health and safety: a systematic and critical review. Int. J. Drug Policy 26:120–29 [Google Scholar]
  57. Wang GS, Roosevelt G, Heard K. 57.  2013. Pediatric marijuana exposures in a medical marijuana state. JAMA Pediatr. 167:7630–33 [Google Scholar]
  58. Thurstone C, Lieberman SA, Schmiege SJ. 58.  2011. Medical marijuana diversion and associated problems in adolescent substance treatment. Drug Alcohol Dep. 118:2–3489–92 [Google Scholar]
  59. Salomonsen-Sautel S, Sakai JT, Thurstone C. 59.  et al. 2012. Medical marijuana use among adolescents in substance abuse treatment. J. Am. Acad. Child Adolesc. Psychiatry 51:7694–702 [Google Scholar]
  60. Wang GS, Roosevelt G, Le Lait MC. 60.  et al. 2014. Association of unintentional pediatric exposures with decriminalization of marijuana in the United States. Ann. Emerg. Med. 63:6684–89 [Google Scholar]
  61. Abrams DI, Couey P, Shade SB. 61.  et al. 2011. Cannabinoid-opioid interaction in chronic pain. Clin. Pharmacol. Ther. 90:6844–51 [Google Scholar]
  62. Lynskey MT, Heath AC, Bucholz KK. 62.  et al. 2003. Escalation of drug use in early-onset cannabis users versus co-twin controls. JAMA 289:4427–33 [Google Scholar]
  63. Bachhuber MA, Saloner B, Cunningham CO, Barry CL. 63.  2014. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Intern. Med. 174:101668–73 [Google Scholar]
  64. Sewell RA, Poling J, Sofuoglu M. 64.  2009. The effect of cannabis compared with alcohol on driving. Am. J. Addict. 18:3185–93 [Google Scholar]
  65. Blows S, Ivers RQ, Connor J. 65.  et al. 2005. Marijuana use and car crash injury. Addiction 100:5605–11 [Google Scholar]
  66. Kelly E, Darke S, Ross J. 66.  2004. A review of drug use and driving: epidemiology, impairment, risk factors and risk perceptions. Drug Alcohol Rev. 23:3319–44 [Google Scholar]
  67. Klonoff H. 67.  1974. Marijuana and driving in real-life situations. Science 186:4161317–24 [Google Scholar]
  68. Lamers CT, Ramaekers JG. 68.  2001. Visual search and urban driving under the influence of marijuana and alcohol. Hum. Psychopharmacol. 16:5393–401 [Google Scholar]
  69. Hartman RL, Huestis MA. 69.  2013. Cannabis effects on driving skills. Clin. Chem. 59:3478–92 [Google Scholar]
  70. Bosker WM, Kuypers KP, Theunissen EL. 70.  et al. 2012. Medicinal Δ(9)-tetrahydrocannabinol (dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is not detected in Standard Field Sobriety Tests. Addiction 107:101837–44 [Google Scholar]
  71. Ramaekers JG, Robbe HW, O'Hanlon JF. 71.  2000. Marijuana, alcohol and actual driving performance. Hum. Psychopharmacol. 15:7551–58 [Google Scholar]
  72. Hall W, Degenhardt L. 72.  2009. Adverse health effects of non-medical cannabis use. Lancet 374:96981383–91 [Google Scholar]
  73. Anthony JC, Warner LA, Kessler RC. 73.  1994. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Exp. Clin. Psychopharmacol. 2:3244–68 [Google Scholar]
  74. Crean RD, Crane NA, Mason BJ. 74.  2011. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J. Addict. Med. 5:11–8 [Google Scholar]
  75. Hunault CC, Mensinga TT, Bocker KB. 75.  et al. 2009. Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC). Psychopharmacology 204:185–94 [Google Scholar]
  76. Schwope DM, Bosker WM, Ramaekers JG. 76.  et al. 2012. Psychomotor performance, subjective and physiological effects and whole blood Δ9-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis. J. Anal. Toxicol. 36:6405–12 [Google Scholar]
  77. Pope HG Jr, Gruber AJ, Hudson JI. 77.  et al. 2002. Cognitive measures in long-term cannabis users. J. Clin. Pharmacol. 42:11 Suppl.41S–7S [Google Scholar]
  78. Bolla KI, Eldreth DA, Matochik JA, Cadet JL. 78.  2005. Neural substrates of faulty decision-making in abstinent marijuana users. NeuroImage 26:2480–92 [Google Scholar]
  79. Schweinsburg AD, Nagel BJ, Schweinsburg BC. 79.  et al. 2008. Abstinent adolescent marijuana users show altered fMRI response during spatial working memory. Psychiatry Res. 163:140–51 [Google Scholar]
  80. Solowij N, Battisti R. 80.  2008. The chronic effects of cannabis on memory in humans: a review. Curr. Drug Abuse Rev. 1:181–98 [Google Scholar]
  81. Brook JS, Stimmel MA, Zhang C, Brook DW. 81.  2008. The association between earlier marijuana use and subsequent academic achievement and health problems: a longitudinal study. Am. J. Addict. 17:2155–60 [Google Scholar]
  82. McClure EA, Lydiard JB, Goddard SD, Gray KM. 82.  2015. Objective and subjective memory ratings in cannabis-dependent adolescents. Am. J. Addict. 24:147–52 [Google Scholar]
  83. Arseneault L, Cannon M, Witton J, Murray RM. 83.  2004. Causal association between cannabis and psychosis: examination of the evidence. Br. J. Psychiatry 184:110–17 [Google Scholar]
  84. Donoghue K, Doody GA, Murray RM. 84.  et al. 2014. Cannabis use, gender and age of onset of schizophrenia: data from the AESOP study. Psychiatry Res. 215:3528–32 [Google Scholar]
  85. Caspi A, Moffitt TE, Cannon M. 85.  et al. 2005. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol. Psychiatry 57:101117–27 [Google Scholar]
  86. Vinkers CH, Van Gastel WA, Schubart CD. 86.  et al. 2013. The effect of childhood maltreatment and cannabis use on adult psychotic symptoms is modified by the COMT ValMet polymorphism. Schizophr. Res. 150:303–11 [Google Scholar]
  87. Di Forti M, Sallis H, Allegri F. 87.  et al. 2014. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr. Bull. 40:61509–17 [Google Scholar]
  88. Manrique-Garcia E, Zammit S, Dalman C. 88.  et al. 2014. Prognosis of schizophrenia in persons with and without a history of cannabis use. Psychol. Med. 44:122513–21 [Google Scholar]
  89. Wu TC, Tashkin DP, Djahed B, Rose JE. 89.  1988. Pulmonary hazards of smoking marijuana as compared with tobacco. N. Engl. J. Med. 318:6347–51 [Google Scholar]
  90. Aldington S, Harwood M, Cox B, Weatherall M. 90.  et al. 2008. Cannabis use and risk of lung cancer: a case-control study. Eur. Respir. J. 31:2280–86 [Google Scholar]
  91. Callaghan RC, Allebeck P, Sidorchuk A. 91.  2013. Marijuana use and risk of lung cancer: a 40-year cohort study. Cancer Causes Control 24:101811–20 [Google Scholar]
  92. Hashibe M, Morgenstern H, Cui Y. 92.  et al. 2006. Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. Cancer Epidemiol. Biomark. Prev. 15:101829–34 [Google Scholar]
  93. Joshi M, Joshi A, Bartter T. 93.  2014. Marijuana and lung diseases. Curr. Opin. Pulm. Med. 20:2173–79 [Google Scholar]
  94. Pletcher MJ, Vittinghoff E, Kalhan R. 94.  et al. 2012. Association between marijuana exposure and pulmonary function over 20 years. JAMA 307:2173–81 [Google Scholar]
  95. Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. 95.  2011. Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab. Dispos. Biol. Fate Chem. 39:112049–56 [Google Scholar]
  96. Jiang R, Yamaori S, Okamoto Y. 96.  et al. 2013. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metab. Pharmacokinet. 28:4332–38 [Google Scholar]
  97. Yamaori S, Koeda K, Kushihara M. 97.  et al. 2012. Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity. Drug Metab. Pharmacokinet. 27:3294–300 [Google Scholar]
  98. Yamaori S, Ebisawa J, Okushima Y. 98.  et al. 2011. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci. 88:15–16730–36 [Google Scholar]
  99. Yamreudeewong W, Wong HK, Brausch LM, Pulley KR. 99.  2009. Probable interaction between warfarin and marijuana smoking. Ann. Pharmacother. 43:71347–53 [Google Scholar]
  100. Kosel BW, Aweeka FT, Benowitz NL. 100.  et al. 2002. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS 16:4543–50 [Google Scholar]
/content/journals/10.1146/annurev-med-050214-013454
Loading
/content/journals/10.1146/annurev-med-050214-013454
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error